Dalteparin: A low-molecular-weight heparin

Annals of Pharmacotherapy

Volumn 31, Issue 2, 1997, Pages 192-203

  Howard, Patricia A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

ABDOMINAL SURGERY; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HIP ARTHROPLASTY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0031034315     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100212     Document Type: Review

References (80)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardham NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rate of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
2. Dalen JE, Paraskos JA, Ockene IS, Alpert JS, Hirsh J. Venous thromboembolism: scope of the problem. Chest 1986;89(suppl):370S-3S.
3. Weinmann EE, Salzman EW. Deep venous thrombosis. N Engl J Med 1994;331;1630-41.
4. Colditz GA, Tuden RI, Oster F. Rates of venous thrombosis after general surgery: combined rates of randomised clinical trials. Lancet 1986;2: 143-6.
5. Clagett GP, Anderson FA, Heit J, Levine MM, Wheeler HB. Prevention of thromboembolism. In: Dalen JE, Hirsh J, eds. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995;108(suppl): 312S-34S.
6. Haake DA, Berkman SA. Venous thromboembolic disease after hip surgery. Clin Orthop 1989;242:212-31.
7. Carter C, Gent M, Leclerc JR. The epidemiology of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis, basic principles and clinical practice. 2nd ed. Philadelphia: JB Lippincott, 1987:1185-98.
8. Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991;17(suppl3):304-12.
9. Package insert. Fragmin (dalteparin). Stockholm, Sweden: Pharmacia, May 12, 1995.
10. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
11. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. In: Dalen JE, Hirsh J, eds. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995;108(suppl): 258S-75S.
12. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990;40:498-530.
13. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AWA. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109.
14. Dautzenberg MD, Bara L, Cornu P, Samama M. Specific anti-Xa activity of LMWH (Kabi 2165, CY216, PK 10169) against the first international standard of LMWH: a collaborative study. Thromb Haemost 1990; 64:490-1.
15. Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP. An international standard for low molecular weight heparin. Thromb Haemost 1988;60:1-7.
16. Fareed J, Walenga JM, Hoppensteadt B, Racanelli A, Coyne E. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemost 1989;15:440-63.
17. Schrader J, Andersson LOA, Armstrong VW, Kundt M, Stibbe W, Scheler F. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis. Semin Thromb Hemost 1990;16(suppl): 41-5.
18. Bratt G, Tornebohm E, Widlund L, Lockner D. Low molecular weight heparin (Kabi 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986;42: 613-20.
19. Simoneau G, Bergmann JF, Kher A, Soria C, Tobelem G. Pharmacokinetics of a low molecular weight heparin (Fragmin) in young and elderly subjects. Thromb Res 1992;66:603-7.
20. Lockner D, Bratt G, Tornebohm E, Aberg W. Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers, Haemostasis 1986;16(suppl 2):8-10.
21. Eriksson BI, Soderberg K, Widlund L, Wandell B, Tengborn L, Risberg B. A comparative study of three low-molecular-weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401.
22. Kakkar W, Sanderson RM, Peers SCE. Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thromboembolism. Haemostasis 1986;16:19-24.
23. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995;82:496-501.
24. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo-controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989;62:1046-9.
25. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, et al. Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis 1986;16(suppl 2):11-8.
26. Koller M, Schoch U, Buchmann P, Larglader F, vonFelten A, Frick PG. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery: a randomized double-blind study versus unfractionated heparin. Thromb Haemost 1986;56:243-6.
27. Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988;18:561-7.
28. Caen JP. A randomized double blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep venous thrombosis in general surgery, Thromb Haemost 1988;59:216-20.
29. Bergqvist D, Burmark US, Frisell J, Guilbaud O, Hallbook T, Horn A, et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. Semin Thromb Hemost 1990;16(suppl):19-24.
30. Hartl P, Brucke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res 1990;57:577-84.
31. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand 1992;71:471-5.
32. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993;341:259-65.
33. Bounameaux H, Huber O, Khabiri E, Schneider PA, Didier D, Rohner A. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg 1993;128:326-8.
34. 125I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Thromb Haemost 1993;69:2-7.
35. Torholm C, Broeng I, Jorgensen PS, Bjerregaard P, Josephsen L, Jorgensen PK, et al. Thromboprophylaxis by low molecular weight heparin in elective hip surgery. J Bone Joint Surg 1991;73B(suppl):434-8.
36. Jorgensen PS, Knudsen JB, Broeng L, Josephsen L, Bjerregaard P, Hagen K, et al. The thromboprophylactic effect of a low molecular weight heparin (Fragmin) in hip fracture surgery. Clin Orthop 1992;278:95-100.
37. Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg 1988;75:1053-7.
38. Eriksson BI, Kalebo P, Anthmyr BA, Wadenvir H, Tengborn L, Risberg B. Prevention of deep venous thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg 1991;73A(suppl):484-93.
39. Dechavanne M, Ville D, Berruyer M, Trepo F, Dalery F, Clermont N, et al. Randomized trial of a low molecular weight heparin (Kabi 2165) versus adjusted dose subcutaneous standard heparin in the prophylaxis of deep venous thrombosis after elective hip surgery. Haemostasis 1989;1: 5-12.
40. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. In: Dalen JE, Hirsh J, eds. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995;108(suppl):335S-51S.
41. Holmstrom M, Berglund C, Granqvist S, Bratt G, Tornebohm E, Lockner D, et al. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg, Thromb Res 1992;67:49-55.
42. Alhenc-Gelas M, Guernic CJL, Vitoux JF, Kher A, Alach M, Fiessinger JN for the Fragmin Study Group. Adjusted versus fixed doses of the low molecular weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:698-702.
43. Lockner D, Bratt G, Tornebohm E, Aberg W, Granqvist S. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis 1986;16(suppl 2):25-9.
44. Bratt GA, Tornebohm E, Johanson M, Aberg W, Granqvist S, Lockner D. Clinical experiences in the administration of a low-molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis. Acta Chir Scand 1988; 543(suppl):96-100.
45. Bratt G, Aberg W, Johanson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990;64:506-10.
46. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
47. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986;16(suppl 2):30-7.
48. Handeland GF, Abildgaard U, Holm HA, Arnesen KE, Dose-adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 1990; 39:107-12.
49. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Circulation 1989;80:935-40.
50. Meyer G, Brenot F, Pacouret G, Simonneau G, Juvin KG, Charbonnier B, et al. Subcutaneous low molecular weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non-massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995;74:1432-5.
51. Marder VJ, Soulen RL, Atichartakarn V, Budzynski AZ, Parulekar S, Kim JR, et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977;84:1018-29.
52. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71:7-11.
53. Quyyumi AA, Diodati JG, Lakatos E, Bonow RO, Epstein SE. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: a pilot study. J Am Coll Cardiol 1993;22:635-41.
54. Nesvold A, Kontny F, Abildgaard U, Dale J. Safety of high doses of low molecular weight heparin (Fragmin) in acute myocardial infarction: a dose-finding study. Thromb Res 1991;64:579-87.
55. Edmondson RA, Cohen AT, Das SK, Wagner MB, Kakkar VV. Lowmolecular-weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344:914-8.
56. Prins MH, Geisema R, Sing AK, Van Heerde LR, den Ottolander GJH. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 1989;19: 245-50.
57. Sanset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990;16(suppl):25-30.
58. Lane DA, Flynn A, Ireland H, Anastassiades E, Curtis JR. On the evaluation of heparin and low molecular weight heparin in hemodialysis for chronic renal failure. Haemostasis 1986;16(suppl 2):38-47.
59. Schrader J, Kandt M, Zurcher C, Kostering H, Scheler F. Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients. Haemostasis 1986;16(suppl2):48-58.
60. Borm JJJ, Krediet R, Sturk A, ten-Gate JW. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study. Haemostasis 1986;26(suppl 2):59-68.
61. Ljungberg B, Blomback M, Johnsson H, Ling L-E. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987;27:31-5.
62. Anastassiades E, Lane DA, Ireland H, Flynn A, Curtis JR. A low molecular weight heparin ("Fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clin Nephrol 1989;32:290-6.
63. Suzuki T, Ota K, Naganuma S, Koshikawa S, Hirasawa Y, Seinosuke N, et al. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan. Semin Thromb Hemost 1990;16(suppl): 46-54.
64. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2337-43.
65. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984;100:535-40.
66. Schmitt BP, Adelman B. Heparin associated with thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993;305:208-15.
67. Ansell JE, Price JM, Shah S, Beckner RR. Heparin-induced thrombocytopenia: what is its real frequency? Chest 1985;88:878-82.
68. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
69. Kikta MJ, Keller MP, Humphrey PW, Silver D. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome? Surgery 1993;114:705-10.
70. Phillips JK, Majumdar G, Hunt BJ, Savidge GF. Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH). Br J Haematol 1993;84:349-50.
71. Melissari E, Das S, Kanthou C, Pemberton KD, Kakkar VV. The use of LMW heparin in treating thromboembolism during pregnancy and prevention of osteoporosis (abstract). Thromb Haemost 1991;65:926.
72. Persson E, Nordenstrom J, Hagenfeldt L, Nilsson-Ehle P. Plasma lipolytic activity after subcutaneous administration of heparin and a low molecular weight heparin fragment. Thromb Res 1987;46:697-704.
73. Myrmel T, Larsen TS, Reikeras O. Lipolytic effect of low molecular weight heparin (Fragmin) and heparin-dihydroergotamine in thromboprophylactic doses during total hip replacement. Scand J Clin Lab Invest 1992;52:741-5.
74. Forestier F, Sole Y, Aiach M, Alhenc-Gelas M, Daffos F. Absence of transplacental passage of Fragmin (Kabi) during the second and third trimesters of pregnancy. Thromb Haemost 1992;67:180-1.
75. Drug topics red book 1996. Montvale, NJ: Medical Economics, 1996; 262.
76. Borris LC, Lassen MR, Jensen HP, Andersen BS, Poulsen KA. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Int J Clin Pharmacol 1994;32:262-8.
77. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip replacement. Ann Intern Med 1993;119:1105-12.
78. Menzin J, Colditz GA, Regan MN, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155:757-64.
79. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334:677-81.
80. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van-der-Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996;334:682-7.